Study shows advanced colorectal cancers at recommended screening age

February 04, 2020

New Orleans, LA - A study analyzing LSU Health's Louisiana Tumor Registry and other NCI-designated tumor registry data found that by the time recommended screening for colorectal begins, cancers have already spread in a high percentage of people. Results report that the rate of colorectal cancer incidence increased by 46.1% from 49 to 50 years of age (the age recommended to start routine colorectal cancer screening) and that 92.9% of the cases of colorectal cancer diagnosed at age 50 were invasive (localized, regional or distant stage.) The study is published in JAMA Network Open, available here.

"The findings of this study indicate that the burden of early-onset of colorectal cancer incidence for 45-49-year olds has been underestimated because asymptomatic colorectal cancers were not detected due to lack of screening," notes Xiao-Cheng Wu, M.D., Professor and Director of the Louisiana Tumor Registry at LSU Health New Orleans School of Public Health.

Data from the National Cancer Institute's Surveillance, Epidemiology & End Results (SEER) 18 registries, representing 28% of the U.S. population, were used to conduct a cross-sectional study of colorectal cancer incidence rates from January 1, 2000, to December 31, 2015, in 1-year age increments (ages 30-60 years) stratified by US region (South, West, Northeast and Midwest), sex, race, disease stage, and tumor location. Statistical analysis was conducted from November 1, 2018, to December 15, 2019. LSU Health New Orleans' Louisiana Tumor Registry is one of the 18 SEER registries. The research team, led by Dr. Jordan Karlitz of the Southeast Louisiana Veterans Health Care System and Tulane University, along with LSU Health New Orleans Louisiana Tumor Registry staff, analyzed a total of 170,434 cases of colorectal cancer. They found steep increases in the incidence of colorectal cancers from 49 to 50 years of age.

The U.S. Preventive Services Task Force recommends screening beginning at age 50.

"As the diagnosis of many of these colorectal cancers was delayed to ages after 50, advanced stage was more likely present at diagnosis," adds Dr. Wu. "This study provides useful evidence for improving colorectal cancer screening policy."
Besides Wu, other members of the research team from LSU Health New Orleans School of Public Health include Qingzhao Yu, Ph.D., Professor in the Biostatistics Program, and Ph.D. student Meijiao Zhou.

LSU Health Sciences Center New Orleans (LSU Health New Orleans) educates Louisiana's health care professionals. The state's health sciences university leader, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public school of Public Health, and Schools of Allied Health Professions, Nursing and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research, the LSU Health New Orleans research enterprise generates jobs and enormous annual economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment or cure disease. To learn more, visit,, or

Louisiana State University Health Sciences Center

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to